Does Capturing Debris During TAVR Prevent Strokes?
NEJM 387:1318-1319, Carroll, J.D. & Saver, J.L., 2022
Effect of a Cerebral Protection Device on Brain Lesions Following Transcatheter Aortic Valve Implantation in Patients with Severe Aortic Stenosis
JAMA 316:592-601,587, Haussig, S.,et al, 2016
Stroke Recurrence in Children with Congenital Heart Disease
Ann Neurol 72:103-111, Rodan, L.,et al, 2012
Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
Stroke 42:227-276, Furie,K.L.,et al, 2011
Does the Combination of Warfarin and Aspirin Have a Place in Secondary Stroke Prevention? No
Stroke 40:1944-1945,1946, Fisher,M., 2009
Does the Combination of Warfarin and Aspirin Have a Place in Secondary Stroke Prevention? Yes
Stroke 40:1942-1943,1946, Furlan,A.J., 2009
Antithrombotic Management of Patients with Prosthetic Heart Valves: Current Evidence and Future Trends
Lancet 374:565-576, Sun,J.C.J.,et al, 2009
Cerebral Ischemic Events After Diagnosis of Mitral Valve Prolapse
Stroke 34:1339-1345, Avierinos,J.,et al, 2003
Management of Anticoagulation Before and AFter Elective Surgery
NEJM 336:1506-1511, Kearon,C.&Hirsh,J., 1997
The Effect of Low-Dose Warfarin on the Risk of Stroke in Patients with Nonrheumatic Atrial Fibrillation
NEJM 323:1505-1511, 1556-15581990., Kistler,J.P.,et al, 1990
Frequency, Etiology, and Prevention of Stroke in Patients with Systemic Lupus Erythematosus
Stroke 20:583-591, Futrell,N.&Millikan,C., 1989
Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke
NEJM 384:2081-2091,2154, Whitlock, R.P.,et al, 2021
Stroke Prevention by Anticoagulants in Daily Practice Depending on Atrial Fibrillation Pattern and Clinical Risk Factors
Stroke 52:3121-3131, Grimaldi-Bensouda, L.,et al, 2021
A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke
NEJM 382:9-19,81, Amarenco, P.,et al, 2020
Use of Dual Antiplatelet Therapy Following Ischemic Stroke
Stroke 51:e78-e80, Dong, J.,et al, 2020
Practice Advisory Update Summary: Patent Foramen Ovale and Secondary Stroke Prevention
Neurol 94:876-885, Messe, S.R.,et al, 2020
Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events with Warfarin Use vs Non-vitamin K Antagonist Oral Anticoagulant Use in Patients with Atrial Fibrillation with a History of Intracranial Hemorrhage
JAMA Network Open 3:e206424, Tsai, C.T.,et al, 2020
Implantable Cardiac Monitoring in the Secondary Prevention of Cryptogenic Stroke
Ann Neurol 88:946-955, Triantafyllou, S.,et al, 2020
Clinical Effectiveness of Direct Oral Anticoagulations vs Warfarin in Older Patients with Atrial Fibrillation and Ischemic Stroke
JAMA Neurol 76:1192-1202, Xian, Y.,et al, 2019
Evidence-Based Management of Patent Foramen Ovale in Patients with Ischemic Stroke
JAMA Neurol 75:147-148, Kamel, H., 2018
Risk of stroke and transient ischaemic attack in patients with a diagnosis of resolved atrial fibrillation: retrospective cohort studies
BMJ 360:k1717, Adderley, N.J.,et al, 2018
Improved Stroke Prevention in Atrial Fibrillation after the Introduction of Non-Vitamin K Antagonist Oral Anticoagulants
Stroke 49:2122-2128, Forslund, T.,et al, 2018
Patent Foramen Ovale Closure, Antiplatelet Therapy or Anticoagulation Therapy Alone for Management of Cryptogenic Stroke?
BMJ 362:k2515, Kuijpers, T.,et al, 2018
Benefits of Emergency Departments Contribution to Stroke Prophylaxis in Atrial Fibrillation
Stroke 48:1344-1352, Coll-Vinent, B.,et al, 2017
Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke
NEJM 377:1022-1032,1006,1093, Saver, J.L.,et al, 2017
Patent Foramen Ovale Closure or Anticoagulation Vs. Antiplatelets after Stroke
NEJM 377:1011-1021,1006,1093, Mas, J.L,et al, 2017
Increasing Prevalence of Vascular Risk Factors in Patients with Stroke
Neurol 89:1985-1994, Otite, F.O.,et al, 2017
Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients
Stroke 47:1555-1561, Shah, A.,et al, 2016
Outcomes with Edoxaban Versus Warfarin in Patients with Previous Cerebrovascular Events
Stroke 47:2075-2082, Rost, N.S.,et al, 2016
Primary Prevention of Stroke
JAMA 316:658-659, Steiger, N. & Cifu, A.S., 2016
The Value of Transesophageal Echocardiography for Embolic Strokes of Undetermined Source
Neuol 87:988-995, Katsanos, A.H.,et al, 2016
Potential Cost-Effectiveness of Ambulatory Cardiac Rhythm Monitoring After Cryptogenic Stroke
Stroke 47:2380-2385, Yong, J.H.E.,et al, 2016
Community Based Case-Control Study of Childhood Stroke Risk Associated with Congenital Heart Disease
Stroke 46:336-340, Fox, C.K.,et al, 2015
Asymptomatic Atrial Fibrillation
JAMA 314:1911-1912, Freedman, S.B. & Lowres, N., 2015
Percutaneous Left Atrial Appendage Closure:Technical Aspects and Prevention of Periprocedural Complications with the Watchman Device
Workd J Cardiol 26:65-75, Mobius-Winkler,S.,et al, 2015
Summary of Evidence-Based Guideline Update: Prevention of Stroke in Nonvalvular Atrial Fibrillation
Neurol 82:716-724, Culebras, A.,et al, 2014
Cryptogenic Stroke and Underlying Atrial Fibrillation
NEJM 370:2478-2486,2532, Sanna, T.,et al, 2014
Atrial Fibrillation in Patients with Cryptogenic Stroke
NEJM 370:2467-2477,2532, Gladstone, D.J.,et al, 2014
Cerebrovascular Events in 21 105 Patients with Atrial Fibrillation Randomized to Edoxaban Versus Warfarin
Stroke 45:2372-2378, Giugliano, R.P.,et al, 2014
Stroke Patients with Suspected Atrial Fibrillation Should be Started on Anticoagulation Pending the Results of Long-Term Cardiac Monitoring
Stroke 44:298-299,302, Diener, H., 2013
Stroke Patients with Suspected Atrial Fibrillation Should NOT be Started on Anticoagulation WHILE AWAITING the Results of Long-Term Cardiac Monitoring
Stroke 44:300-301,302, Katsnelson, M. & Sacco, R., 2013
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
NEJM 368:1092-1100,1152, Carroll, J.D.,et al, 2013
Percutaneous Closure of Patent Foramen Ovale in Cryptogenic Embolism
NEJM 368:1083-1091,1152, Meier, B.,et al, 2013
Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation
Stroke 44:1676-1681, Harringotn, A.,et al, 2013
Summary of Evidence-Based Guideline: Periprocedural Management of Antithrombic Medications in Patients with Ischemic Cerebrovascular Disease
Neurol 80:2065-2069, Armstrong, M.,et al, 2013
Edoxaban Versus Warfarin in Patients with Atrial Fibrillation
NEJM 369:2093-2104, Giugliano, R.P.,et al, 2013
Left Atrial Catheter Ablation and Ischemic Stroke
Stroke 43:265-270, Haeusler, K.G.,et al, 2012
Cost-Effectiveness of Dabigatran Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation and Prior Stroke or Transient Ischemic Attack
Stroke 43:881-883, Kamel,H.,et al, 2012
Closure or Medical Therapy for Cryptogenic Stroke with Patent Foramen Ovale
NEJM 366:991-999,1048, Furlan,A.J.,et al, 2012